



RECEIPT
FILE COPY

PATENT
Attorney Docket No. 3260.0047-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVE

OCT 06 2000

TECH CENTER 1500/2300

In re Application of:

John Ernest SIMS

Serial No.: 09/612,921

Filed: July 10, 2000

For: IL-1 Delta DNA AND POLYPEPTIDES

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

REQUEST FOR CORRECTED FILING RECEIPT

We are forwarding herewith a copy of a Filing Receipt which has been received from the U.S. Patent and Trademark Office. There is an error in the Filing Receipt where continuing information was omitted.

In Continuing Data as Claimed by Applicant, after "WHICH CLAIMS BENEFIT OF 60/071,074 01/09/1998", kindly add --and 60/087,393 06/01/1998--.

The correct information is shown in red highlight.

It is respectfully requested that a corrected Filing Receipt be issued as soon as possible.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By:



Salvatore J. Arrigo

Reg. No. 46,063

Tel: (202) 408-4000

Fax: (202) 408-4400

Email: arrigos@finnegan.com

Date: September 21, 2000


LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

FILING RECEIPT



OC000000005340864

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

JBF/SJA/VSD

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
--------------------	-------------	--------------	---------------	-----------------	----------	------------	------------

09/612,921

07/10/2000

1645

1086

03260.0047

RECEIVED

OCT 06 2000

TECH CENTER 1600/2900

Date Mailed: 08/21/2000

Finnegan Henderson Farabow Garrett & Dunner LLP
1300 I St N W
Washington, DC 20005-3315

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

John E. Sims, Seattle, WA ;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CON OF PCT/US99/00514 01/08/1999

WHICH CLAIMS BENEFIT OF 60/071,074 01/09/1998 ~~and 60/087,393 06/01/1998~~

Foreign Applications

If Required, Foreign Filing License Granted 08/21/2000

RECEIVED

AUG 24 2000

Title

II-1 delta DNA and polypeptides

FINNEGAN, HENDERSON, FARABOW,
GARRETT AND DUNNER, LLP

Preliminary Class

435

Data entry by : ROBINSON, YOLANDA

Team : OIPE

Date: 08/21/2000



AUG 25 2000

8/21/00 12:06 PM

RECEIVED

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

OCT 06 2000

TECH CENTER 1600/2900

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231

**FILE COPY
RECEIVED**

UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 06 2000

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICEWASHINGTON, DC 20590
TECH CENTER 1600/2900
www.uspto.gov

Bib Data Sheet

SERIAL NUMBER 09/612,921	FILING DATE 07/10/2000 RULE -	CLASS 435	GROUP ART UNIT 1645	ATTORNEY DOCKET NO. 03260.0047
------------------------------------	---	---------------------	-------------------------------	--

APPLICANTS

John E. Sims, Seattle, WA ;

**** CONTINUING DATA *******

THIS APPLICATION IS A CON OF PCT/US99/00514 01/08/1999
WHICH CLAIMS BENEFIT OF 60/071,074 01/09/1998
WHICH CLAIMS BENEFIT OF 60/087,393 06/01/1998

**** FOREIGN APPLICATIONS *********IF REQUIRED, FOREIGN FILING LICENSE**

GRANTED ** 08/21/2000 -

Foreign Priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no	STATE OR COUNTRY WA	SHEETS DRAWING -	TOTAL CLAIMS 29	INDEPENDENT CLAIMS 6
35 USC 119 (a-d) conditions met <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged	Examiner's Signature	Initials		

ADDRESS

Finnegan Henderson Farabow Garrett & Dunner LLP
1300 I St N W
Washington, DC 20005-3315

TITLE

II-1 delta DNA and polypeptides

FILING FEE RECEIVED 1086	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees
		<input type="checkbox"/> 1.16 Fees (Filing)
		<input type="checkbox"/> 1.17 Fees (Processing Ext. of time)
		<input type="checkbox"/> 1.18 Fees (Issue)
		<input type="checkbox"/> Other _____
		<input type="checkbox"/> Credit